Integrated BioPharma, Inc. (INBP)
| Previous Close | 0.2182 |
| Open | 0.2182 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.2182 - 0.2182 |
| 52 Week Range | 0.1700 - 0.3800 |
| Volume | |
| Avg. Volume | 2,120 |
| Market Cap | 6.568M |
| Beta (5Y Monthly) | 0.52 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | May 10, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ACCESSWIREIntegrated BioPharma Reports Results for its Quarter Ended March 31, 2024
HILLSIDE, NJ / ACCESSWIRE / May 10, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended March 31, 2024. Revenue for each of the quarters ended March 31, 2024 and 2023 were approximately ...
- ACCESSWIRE
Integrated BioPharma Reports Results for its Quarter Ended December 31, 2023
HILLSIDE, NJ / ACCESSWIRE / February 12, 2024 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended December 31, 2023. Revenue for the quarter ended December 31, 2023 was $11.5 million ...
- ACCESSWIRE
Integrated BioPharma Reports Results for its Quarter Ended September 30, 2023
HILLSIDE, NJ / ACCESSWIRE / November 9, 2023 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP") reports its financial results for the quarter ended September 30, 2023.Revenue for the quarter ended September 30, 2023 was $12.9 million ...
